MyMD Pharmaceuticals Inc [NASDAQ: MYMD] price surged by 3.58 percent to reach at $0.01. The company report on October 19, 2023 at 9:00 AM that MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain.
– Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours.
– Results suggest Supera-CBD may target specific pain pathways, lessening the potential for side effects.
A sum of 4412387 shares traded at recent session while its average daily volume was at 595.01K shares. MyMD Pharmaceuticals Inc shares reached a high of $0.367 and dropped to a low of $0.29 until finishing in the latest session at $0.35.
The one-year MYMD stock forecast points to a potential upside of 98.91. The average equity rating for MYMD stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on MyMD Pharmaceuticals Inc [MYMD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYMD shares is $32.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYMD stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for MyMD Pharmaceuticals Inc is set at 0.05 The Price to Book ratio for the last quarter was 1.07, with the Price to Cash per share for the same quarter was set at 0.19.
MYMD Stock Performance Analysis:
MyMD Pharmaceuticals Inc [MYMD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.09. With this latest performance, MYMD shares dropped by -25.03% in over the last four-week period, additionally sinking by -82.75% over the last 6 months – not to mention a drop of -82.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYMD stock in for the last two-week period is set at 40.11, with the RSI for the last a single of trading hit 43.11, and the three-weeks RSI is set at 38.69 for MyMD Pharmaceuticals Inc [MYMD]. The present Moving Average for the last 50 days of trading for this stock 0.4809, while it was recorded at 0.3336 for the last single week of trading, and 1.3440 for the last 200 days.
Insight into MyMD Pharmaceuticals Inc Fundamentals:
Return on Total Capital for MYMD is now -79.12, given the latest momentum, and Return on Invested Capital for the company is -78.92. Return on Equity for this stock declined to -79.27, with Return on Assets sitting at -71.77. When it comes to the capital structure of this company, MyMD Pharmaceuticals Inc [MYMD] has a Total Debt to Total Equity ratio set at 0.96. Additionally, MYMD Total Debt to Total Capital is recorded at 0.96, with Total Debt to Total Assets ending up at 0.81. Long-Term Debt to Equity for the company is recorded at 0.52, with the Long-Term Debt to Total Capital now at 0.51.
MyMD Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.71 and a Current Ratio set at 1.71.
MyMD Pharmaceuticals Inc [MYMD] Institutonal Ownership Details
The top three institutional holders of MYMD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in MYMD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in MYMD stock with ownership which is approximately 5.7994%.